Shravanti Macherla

Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer

Caroline A. Nebhan, Alessio Cortellini, Weijie Ma et al. · JAMA Oncology · 2021 · 152 citations · Full text

Medicine, Immunology, Oncology +17

Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer

Abdul Rafeh Naqash, Justin McCallen, Emma Mi et al. · Journal for ImmunoTherapy of Cancer · 2023 · 55 citations · Full text

Life Sciences, Immunology, Oncology +14

Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition

Abdul Rafeh Naqash, Ebenezer Appah, Li V. Yang et al. · Journal for ImmunoTherapy of Cancer · 2019 · 37 citations · Full text

Medicine, Oncology, Pharmacology +16

Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC

Biagio Ricciuti, Abdul Rafeh Naqash, Jarushka Naidoo et al. · JTO Clinical and Research Reports · 2020 · 25 citations · Full text

Life Sciences, Immunology, Oncology +17

Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non–small-cell Lung Cancer

Kartik Sehgal, Anushi Bulumulle, Heather Brody et al. · Clinical Lung Cancer · 2020 · 22 citations · Full text

Medicine, Oncology, Pharmacology +14